METXF (ME Therapeutics Holding) FCF Margin %: 0.00% (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

METXF ME Therapeutics Holding Inc METXF
14 GF Score
Price $3.25
! 1 Warning Sign
View Full Analysis

What is ME Therapeutics Holding FCF Margin %?

ME Therapeutics Holding METXF 14 FCF Margin % is 0.00% as of May. 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 956 Biotechnology companies, ME Therapeutics Holding ranks worse than 104602.41% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ME Therapeutics Holding's Free Cash Flow for the three months ended in May. 2026 was $-0.22 Mil. ME Therapeutics Holding's Revenue for the three months ended in May. 2026 was $0.00 Mil. Therefore, ME Therapeutics Holding's FCF Margin % for the quarter that ended in May. 2026 was 0.00%.

As of today, ME Therapeutics Holding's current FCF Yield % is -2.26%.

The historical rank and industry rank for ME Therapeutics Holding's FCF Margin % or its related term are showing as below:


METXF's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -80.565
* Ranked among companies with meaningful FCF Margin % only.

ME Therapeutics Holding FCF Margin % Related Terms

ME Therapeutics Holding FCF Margin % Historical Data

* Premium members only.

The historical data trend for ME Therapeutics Holding's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding FCF Margin % Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24 Aug25
FCF Margin %
0.00 0.00 0.00 0.00

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

METXF vs VRTX, REGN, RVMD: FCF Margin % Comparison

For the Biotechnology subindustry, ME Therapeutics Holding's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ME Therapeutics Holding FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's FCF Margin % falls into.


METXF
14GF Score
ME Therapeutics Holding Inc METXF
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ME Therapeutics Holding FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ME Therapeutics Holding's FCF Margin for the fiscal year that ended in Aug. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Aug. 2025 )/Revenue (A: Aug. 2025 )
=-0.782/0
= %

ME Therapeutics Holding's FCF Margin for the quarter that ended in May. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: May. 2026 )/Revenue (Q: May. 2026 )
=-0.221/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
ME Therapeutics Holding (METXF) has a FCF Margin % of 0.00% as of May. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ME Therapeutics Holding and its competitors. According to the industry distribution chart, ME Therapeutics Holding ranks #999999 out of 956 companies in the Biotechnology industry.
Is ME Therapeutics Holding's FCF Margin % too high?
ME Therapeutics Holding's current FCF Margin % is 0.00%. Based on the distribution chart, ME Therapeutics Holding ranks #999999 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ME Therapeutics Holding ranks #999999 out of 956 companies for FCF Margin %. This places ME Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current FCF Margin % is 0.00% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ME Therapeutics Holding Business Description

Other Exchanges METX:Canada
Address 2665 East Mall, Room 249, Vancouver, BC, CAN, V6T 1Z4
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score

Get the complete analysis for METXF

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price